APA (7th ed.) Citation

S, K., T, F., J, I., A, K., T, T., N, M., . . . S, U. (2023). Correction: Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study. BMC nephrology, 24(1), 22. https://doi.org/10.1186/s12882-023-03067-8

Chicago Style (17th ed.) Citation

S, Kameda, Fujii T, Ikeda J, Kageyama A, Takagi T, Miyayama N, Asano K, Endo A, and Uezono S. "Correction: Unfractionated Heparin Versus Nafamostat Mesylate for Anticoagulation During Continuous Kidney Replacement Therapy: An Observational Study." BMC Nephrology 24, no. 1 (2023): 22. https://doi.org/10.1186/s12882-023-03067-8.

MLA (9th ed.) Citation

S, Kameda, et al. "Correction: Unfractionated Heparin Versus Nafamostat Mesylate for Anticoagulation During Continuous Kidney Replacement Therapy: An Observational Study." BMC Nephrology, vol. 24, no. 1, 2023, p. 22, https://doi.org/10.1186/s12882-023-03067-8.